So Far

Fly Charts: Iran's Oil Impact and the Route to Resurgent M&A

From a generic drug surge to European bond realities, here are four charts that tell you what you need to know in business today.
Photographer: Spencer Platt

Good morning! This is Fly Charts, the daily charts-only newsletter from Gadfly; sign up here. From a generic drug surge to European bond realities, here are four charts that tell you what you need to know in business today.

October Surprise

Iran may be grabbing headlines, but U.S. production trends are likely to have a bigger impact on oil prices.

Data: Energy Information Administration; graphic by Bloomberg Gadfly

Comeback Year?

The growing trend of companies doing deals outside their wheelhouse may lead to an M&A rebound in 2018.

Source: Bloomberg

Back to Reality?

Bond investors appear to have finally noticed the ECB's efforts to wean markets from life support.

Source: Bloomberg

Rewrite the Record Book

Generic drug approvals have skyrocketed under new FDA chief Scott Gottlieb -- which will have a far-ranging and often negative impact on the pharmaceutical industry.

Source: FDA

And don't miss Gadfly's toast to those who left the business scene in 2017, including farewells to Travis Kalanick, Jeff Immelt, and Mickey Drexler. 

This column does not necessarily reflect the opinion of Bloomberg LP and its owners.

    To contact the author of this story:
    Max Nisen in New York at mnisen@bloomberg.net

    To contact the editor responsible for this story:
    Mark Gongloff at mgongloff1@bloomberg.net

    Before it's here, it's on the Bloomberg Terminal.
    LEARN MORE